CareConnect Warmline

This Philadelphia hotline provides timely access to a range of harm reduction, treatment, and recovery services, including initiation of buprenorphine

Medications for opioid use disorder (MOUD), such as buprenorphine, are the gold standard for treatment of opioid use disorder (OUD), but are often difficult to access. To increase their availability, a team at the Center for Addiction Medicine of the University of Pennsylvania initiated CareConnect, leveraging new regulatory flexibilities that allow for same day prescribing of buprenorphine via telephone. The program includes clinicians who provide OUD care and a substance use navigator team that assesses patients and links them to external OUD care programs based in primary care or specialty behavioral health.

No insurance is required to use CareConnect and callers can obtain information about the following services:

  • Real time assistance to access resources, including information for clinicians and family members

  • Education and harm reduction support

  • Same-day buprenorphine initiation

  • Access to peer support

The website provides contact information and links to external resources, including where to find fentanyl test strips and naloxone, assistance for pregnant individuals, and help with housing and food insecurity in the Philadelphia area. The program is described in this news release and this evaluation study.

CareConnect offers consistent same-day buprenorphine treatment access in Philadelphia, saving hundreds of visits to the emergency department and ensuring hundreds of people get the care they need rather than no care at all.

Continuum of Care
Treatment
Recovery
Harm Reduction
Type of Evidence
Peer-reviewed
Response Approach
Educational
Family Support
Medications for Opioid Use Disorder
Overdose prevention
Recovery coaching
Peer-reviewed Article

Evidence of Program Effectiveness

"Since launching in November 2021, CareConnect has connected with more than 350 patients as of August 2022. We continue to assess capacity as the service grows and plan to hire additional SUNs as volume increases. Visits have increased for both total calls (n 5 371) and buprenorphine prescription encounters (n 5 249) during the first 11 months of the program from November 2021 through September 2022. Of the nonprescription encounters, 47% were providers seeking information, and 53% were patients or family members." Lowenstein, M. et al., 2022.